Acumen Pharma - רווח נקי למניה אחת בשנים עשר החודשים האחרונים ABOS

The business model of Acumen Pharmaceuticals (ABOS) relies on the efficacy of ACU193 in treating Alzheimer's disease, where the key success factor will be the slowing of cognitive decline. A management team composed of specialized scientists is betting on the flawless precision of clinical trials. This chart of the market price demonstrates an EPS (TTM) of 29.60, while R&D development is supported by co-financing from a major global partner.
Acumen Pharma - פילוחים אנליטיים ומדדי מפתח (ABOS)

This indicator captures the dynamics of earnings per share compared to the same period last year, identifying deviations of current profitability from historical averages. By analyzing the annual EPS growth rate over the last 12 months, an investor will observe high volatility in the metrics of Acumen Pharmaceuticals (ABOS), driven by a lack of revenue and intensive R&D expenditures for Alzheimer's disease treatments.